News

Plus Therapeutics to Present Data from ReSPECT-GBM™ Clinical Trial at the European Society for Medical Oncology Congress 2022

AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,…

2 years ago

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer’s Disease

Mechanism of Action of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) is the activation of SIGMAR1 Endogenous increase in SIGMAR1 activation as…

2 years ago

Tilray Medical Receives Verification From the Natural Health Science Foundation in Australia and New Zealand

Natural Health Science Foundation Assessment Further Verifies Tilray Medical’s High-Quality Standard and its CBD100 Product for Clinical Trial UseSYDNEY, Australia,…

2 years ago

Miromatrix Announces Participation in Upcoming Gilmartin Emerging Growth Company Showcase

EDEN PRAIRIE, Minn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a…

2 years ago

IsoPlexis Announces the Appointment of former Luminex Corporation Chairman and CEO, Nachum “Homi” Shamir to its Board of Directors

BRANFORD, Conn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the…

2 years ago

Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS

CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a…

2 years ago

Algernon Pharmaceuticals Announces Closing of Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 23, 2022…

2 years ago

Lucira Health to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

EMERYVILLE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused…

2 years ago

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME

IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics’ proprietary CD8αβ co-receptor engaging functional CD4 and CD8 T cells directed against…

2 years ago

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age

Updated analysis from 34 cases occurring at least seven days following a three-dose regimen showed 73.2% vaccine efficacy among children…

2 years ago